These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28215414)

  • 21. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.
    Bangalore S; Amoroso N; Fusaro M; Kumar S; Feit F
    Circ Cardiovasc Interv; 2013 Aug; 6(4):378-90. PubMed ID: 23922145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis.
    Palmerini T; Benedetto U; Biondi-Zoccai G; Della Riva D; Bacchi-Reggiani L; Smits PC; Vlachojannis GJ; Jensen LO; Christiansen EH; Berencsi K; Valgimigli M; Orlandi C; Petrou M; Rapezzi C; Stone GW
    J Am Coll Cardiol; 2015 Jun; 65(23):2496-507. PubMed ID: 26065988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Valgimigli M; Frati G; Kedhi E; Smits PC; Kaiser C; Genereux P; Galatius S; Kirtane AJ; Stone GW
    J Am Coll Cardiol; 2013 Aug; 62(6):496-504. PubMed ID: 23747778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
    Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1552-62. PubMed ID: 26493248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization.
    Das P; Moliterno DJ; Charnigo R; Mukherjee D; Steinhubl SR; Sneed JD; Booth DC; Ziada KM
    J Invasive Cardiol; 2006 Sep; 18(9):405-8. PubMed ID: 16954577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group.
    Brodie BR; Stuckey T; Downey W; Humphrey A; Bradshaw B; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Smith H; Edmunds J; Varanasi J; Simonton CA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):405-14. PubMed ID: 19463338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
    Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
    Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
    JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.
    De Luca G; Dirksen MT; Spaulding C; Kelbaek H; Schalij M; Thuesen L; van der Hoeven B; Vink MA; Kaiser C; Musto C; Chechi T; Spaziani G; Díaz de la Llera LS; Pasceri V; Di Lorenzo E; Violini R; Cortese G; Suryapranata H; Stone GW;
    Arch Intern Med; 2012 Apr; 172(8):611-21; discussion 621-2. PubMed ID: 22529227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis of long-term outcomes for drug-eluting stents versus bare-metal stents in primary percutaneous coronary interventions for ST-segment elevation myocardial infarction.
    Wallace EL; Abdel-Latif A; Charnigo R; Moliterno DJ; Brodie B; Matnani R; Ziada KM
    Am J Cardiol; 2012 Apr; 109(7):932-40. PubMed ID: 22221949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Drug-Eluting and Bare Metal Stents in Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis.
    Lu R; Tang F; Zhang Y; Zhu X; Zhu S; Wang G; Jiang Y; Fan Z
    J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27821401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term risk of clinical events from stenting side branches of coronary bifurcation lesions with drug-eluting and bare-metal stents: an observational meta-analysis.
    Zamani P; Kinlay S
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):202-12. PubMed ID: 20824754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation.
    Auer J; Leitner A; Berent R; Lamm G; Lassnig E; Krennmair G
    Atherosclerosis; 2010 Jun; 210(2):503-9. PubMed ID: 20060973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
    Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
    JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-hospital and one year outcomes with drug-eluting versus bare metal stents in large native coronary arteries: a report from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.
    Gordon PC; Cohen DJ; Kleiman NS; Montgomery JA; Semder CA; Kennedy KF; Keyes MJ; Piana RN;
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):E356-64. PubMed ID: 22511502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
    Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.